and over been since Thank good days. transformed call. our has largely those Bennett, you, everyone. XX It Yet XX only the last been days morning, company earnings has
patients call, results To the X a since positive announced investors positive lead years. Phase for Sublingual last treatment over our to Libervant be Buccal we $XX in candidate, high-quality clusters interaction million for capital our new have X Anaphylm specific, and in Film, III Film and aged of FDA product raised for from FDA received diazepam approval epinephrine seizure
the these have accomplishments initiatives. also days We for XX was while a the progressing realized This company. company's truly long-term growth remarkable
over all management the for reach the last for team, we other members is have gratifying the transformation been and of me planning side years. it X to of the of For the
Anaphylm rapidly to clinic. the in continue We progress
As to before shared adult study, have for exposure to allergen and you, our these refer we FDA. self-administration the study study. previously our with application our our temperature/pH perform we as X We filing supportive ready studies with is
well underway is to less back remains to with comments a FDA submitted responses days. within complete days. for the this We from receive and I pleased study XX dosing were in and XX self-administration quarter. our positive studies the am protocols receive request exposure track that say our to allergen than on pleased to temperature/pH to We our FDA
commencing complete in currently studies process We now quarter. expect of all of the studies. end the both the third X We before are to
in to results we be will our that August. quarter from second a current by at able guidance is provide these of least call portion Our clinical studies earnings
supplemental each of website. be in studies We materials, these can our have our provided which found on more details on
This study. of us studies these third our the seek in pre-NDA conduct the FDA our the around to could and pre-NDA end upon of with pediatric our occur this completion valuable Under meeting the development process. save scenario, may may quarter. before time meeting We conducting
optimal As for model towards time we Anaphylm. progress our filing, the on also spending are distribution we more identifying
all pharmaceutical complicated a the industry know, is preparation. requires and significant distributing medication we As in process
it for I Unfortunately, questions. I millions it? results every common are often that is complex day. and my are it? These to I unanswered caregivers medication of faced by be owe? to Americans What my and How Will patients, much will many in and navigate medication replace covered? need afford if questions Can lose
months, Over time Anaphylm of is understand is of in strategy with put the of for we we experts ripe where change. hands to our payers industry innovation that and market to it spend belongs, will This if drive amount we area significant help coming optimal the that so practical, an a seek and will access patients.
have We such planning. work and to activities launch typical marketing begun packaging design, also on force sales as materials
and our business engaged hired build will year. a variety experts, part this of have the We throughout commercial and to continue of key we
Libervant. Now to let me turn
me obtain week, heard were pleased FDA say you patient to approval last the population. to for access market As and X-year-old we X-
obtaining reimbursement, begun are prescriptions We and received. process continue to government they the of commercial as have and non-Medicaid we already fill
Anaphylm, to examine our distribution to we model Libervant. continue Similar for
very have a that We through managed can a point call small team. be concentrated internal
or patients. either these sales expect market expand young team other we marketing on, our goes to with and time to collaborate expand organizations for access As internal
X- are X-year-old year within There and grow. to filled continues prescriptions the XX,XXX every this to over population, number
only We very treatment this for oral of first are clusters and seizure to the the excited to medication patient rescue population. important provide FDA-approved finally
provider that happy" the that she use "so feedback fact, providers were be longer rectal health provider care families us very us excited told health centers to were many extremely to been going another administer gel. no have health In because gel. And has to to from early and rectal care refusing was the her daycare care caregivers One positive. told
amount quarter our the that and remains remained our first over circulation skin epinephrine to in initial the the the our gel. continue promising. platform of application or clinical prodrug with Adrenaverse epinephrine study We our topical the completed program, on found data This We after in progress was AQST-XXX study measured time human first gel. of
results competitive our product for we data compelling the found continue the releasing not reasons, to are we development efforts. enough While
expect in of over more year. to aim be back in half clinic program continue and the to the second on providing information for the We the summer this
Our base remains steady. business
First quarter were shipments significantly higher first the than of year. last quarter
sum have about the been of never up, To it I prospects more the company. excited
These track into phase an to believe We to a management successful necessary we have great emerging record. and blocks I technology, continue growth story. the building team basic an our and our experienced in industry. be transformation will growing from progress are
Libervant; to: manage the quarter from ensure or August: on For before supportive distribution the as development Anaphylm business. patient the to availability base data efficiently continue as AQST-XXX capabilities balance second announce of our the our year, studies on-label of rapidly call clinical expect in earnings clinical we to our advance for can; maximum we expand and
call over I that, the turn will Ernie. to With
